Zhejiang Starry Pharmaceutical603520.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Zhejiang Starry Pharmaceutical (603520.SH) trades at a P/E of 168.00x, P/B of 1.43x, P/S of 1.25x, and a dividend yield of 3.73%.
Longitudinal percentile comparison: P/E sits at the 85th percentile over the trailing 10Y window (vs. 39th percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 16th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 89th percentile within its industry and the 89th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.73%, ranking at the 100th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 80.2 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Zhejiang Starry Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 603520 · SSE: 603520 · 603520
Want the full picture on whether Zhejiang Starry Pharmaceutical (603520.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 168.00 | ||||||
| P/B (MRQ) | 1.43 | ||||||
| P/S (TTM) | 1.25 | ||||||
| Dividend Yield | 3.73% | ||||||
| Buyback + Div Yield | 3.73% |